Foldax announced that the first 30 patients have been treated outside of the U.S., in the Indian clinical trial...
Read moreFoldax announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a...
Read moreFoldax Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective...
Read moreFoldax announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial...
Read moreFoldax has announced the presentation of results from the first animal study of its transcatheter valve from the TRIA...
Read moreFoldax announced publication of the first clinical results for its TRIA™ biopolymer heart valve - the first polymer valve...
Read moreFoldax® announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve. The...
Read moreFoldax announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a diseased mitral valve....
Read moreFoldax is looking to reinvent every aspect of the heart valve—from material, to design, to manufacturing. Foldax is working...
Read moreFoldax has announced the publication of a research paper in Advanced NanoBiomed Research that concluded that its LifePolymer biopolymer...
Read more